Eloxx Pharmaceuticals (OTC: ELOX)
Eloxx Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Eloxx Pharmaceuticals Company Info
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.
Valuation
Earnings Transcripts
Eloxx Pharmaceuticals, Inc. (ELOX) Q4 2020 Earnings Call Transcript
ELOX earnings call for the period ending December 31, 2020.
Eloxx Pharmaceuticals, Inc. (ELOX) Q3 2020 Earnings Call Transcript
ELOX earnings call for the period ending September 30, 2020.
Eloxx Pharmaceuticals, Inc. (ELOX) Q2 2020 Earnings Call Transcript
ELOX earnings call for the period ending June 30, 2020.
Eloxx Pharmaceuticals, Inc. (ELOX) Q1 2020 Earnings Call Transcript
ELOX earnings call for the period ending March 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.